Table 3.
Cost and Resource Utilization Model Inputs for SCR
| Costs | Utilization Rate | Unit Cost | Frequency | Total Cost | Source |
|---|---|---|---|---|---|
| SCR cost | 100% | S$5149.7 | 1 | S$5149.7 | For cost: published data from Singapore government,34 For dose: clinician advice and NHS Network Site Specific group.45 |
| Total admin cost | 100% | S$2170.5 | 1 | S$2170.5 | For IV cost: published data from Singapore government,34 For SC cost: Private cost – clinicians (converted to public cost)# |
| Inpatient hospital | 100% | S$1393.2 | 28 | S$39009.9 | For LOS: clinician advice, similar to,46 For cost: published data from Singapore government.34 |
| Subsequent allo-HSCT | 43.14% | S$158,742 | 1 | S$68477.0 | For rate of allo-HSCT.11 The cost of allo-HSCT includes treatment cost, follow up cost and AE cost. For treatment cost of allo-HSCT: published data from Singapore government34 (S$150,000). For follow up cost for one year post allo-HSCT (S$8825): Private cost – clinicians (converted to public cost)# For AE %: Clinician input For AE cost (S$5442): published data from Singapore government.34 |
| Other serious AEs | 100% | S$16774.7 | Multiple | S$16774.7 | For % of events.49 For cost: Private cost – clinicians (converted to public cost)# |
| Heath States costs | |||||
| EFS | For the frequency of tests in EFS state at different years for comparators: clinician advicea For cost of tests: Private cost – clinicians (converted to public cost)# |
||||
| Year1: | S$954.1 | ||||
| Year2: | S$323.3 | ||||
| Year 3–5: | S$165.2 | ||||
| Post year 5: | S$165.2 | ||||
| Progressive disease | S$1908.2 | Assumed to be double of EFS state of chemotherapies during year 1. Assumed to be same for all comparators and TIS. | |||
| Death | 0 | 0 | 0 | ||
| Terminal care cost one time | S$3210.9 | Public cost50 | |||
Notes: #Cost from private hospital was converted to public hospital value by applying a conversion factor of 2.18, aThe EFS costs included various cost items, consultant visit, hematology panel, coagulation panel, chemistry panel, cerebrospinal fluid, serum test, B and T cell test, electrocardiogram, bone marrow aspirate, bone marrow biopsy, echocardiogram, liver function test.
Abbreviations: AE, adverse event; allo-HSCT, allogenic hematopoietic stem cell transplantation; EFS, event-free survival; IV, intravenous; LOS, length of stay; NHS, national health services; SC, subcutaneous; SCR, Salvage chemotherapy regimen; TIS, tisagenlecleucel.